ORMELOXIFENE

ORMELOXIFENE: Ormeloxifene, also known by the brand name Centchroman, is a non-hormonal selective estrogen receptor modulator (SERM). It is primarily used as a contraceptive and for the treatment of dysfunctional uterine bleeding and as a supportive therapy in regularizing menstruation.

Ormeloxifene works by binding to estrogen receptors in target tissues like the endometrium, cervix, and uterus. As a SERM, it acts as an agonist in some tissues (e.g., bone, liver) and as an antagonist in others (e.g., breast, uterus). By this mechanism, ormeloxifene reduces the endometrial proliferation stimuli caused by estrogen, resulting in the inhibition of ovulation and prevention of implantation.

The recommended dose of ormeloxifene is 30 mg, taken orally, once a week. It is important to start the drug on the first or second day of the menstrual cycle.

As for side effects, ormeloxifene has been reported to cause mild and transient adverse effects. The most commonly observed side effects include nausea, vomiting, headache, breast tenderness, and spotting or breakthrough bleeding. These side effects are usually self-limiting and do not require discontinuation of the drug.

It is important to note that ormeloxifene does not protect against sexually transmitted infections (STIs) and should not be used as a substitute for condoms or other barrier methods of contraception. It is also contraindicated in patients with liver disease, thromboembolic disorders, and hormone-related malignancies.

Overall, ormeloxifene is a safe and effective non-hormonal contraceptive option for women seeking long-term contraception or treatment for dysfunctional uterine bleeding. It is essential to consult with a healthcare professional before initiating ormeloxifene to determine its suitability and proper usage based on individual medical history and needs.